SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Summit Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$15.57+0.94 (+6.43%)
Close on Oct 19, 2026
- Market cap
- $12.12B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.42 (−25.82%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $12.12B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 19.23
- Dividend yield
- –
- Free cash flow yield
- -3.80%
Fundamentals
- Net income
- -$856.09M
- EPS, diluted
- -$1.12
- Free cash flow
- -$459.82M
- Book value per share
- $0.81
- Diluted shares
- 778M
Nine years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
–
Net income
-$856.09M
EPS, diluted
-$1.12
Free cash flow
-$459.82M
Reported periodTrailing twelve months